The impact of postoperative adjuvant chemotherapy on the development of nonalcoholic fatty liver disease after pancreatoduodenectomy.
Nonalcoholic fatty liver disease (NAFLD) after pancreatoduodenectomy (PD) is increasingly being recognized as a late postoperative complication, but the main causes have not been fully investigated. This study aimed to clarify the relationship between NAFLD after PD and postoperative adjuvant chemotherapy, focusing particularly on the adjuvant chemotherapy regimens administered.



We retrospectively reviewed the medical records of 154 patients who underwent PD from April 2007 to December 2013, to identify the clinicopathologic factors most strongly influencing NAFLD development after PD. Moreover, the postoperative adjuvant chemotherapeutic regimen and the course after the cessation of adjuvant chemotherapy were examined in detail.



The incidence of postoperative NAFLD was 26.6% (41/154). The incidence of NAFLD was significantly higher in the patients with than in those without adjuvant chemotherapy: 38% versus 19% (P = 0.016). Multivariate analysis identified postoperative adjuvant chemotherapy (P = 0.021) and remnant pancreatic volume (P < 0.0001) as independent risk factors. The prevalence of NAFLD after PD was higher in patients treated with the S-1 regimen than in those given either regimens such as those containing gemcitabine or no adjuvant chemotherapy. Recovery from NAFLD 1 y after the cessation of adjuvant chemotherapy was observed in 54.5% (12/22) of patients receiving this treatment. In those treated with the S-1 regimen, improvement was more frequent than in those not receiving adjuvant chemotherapy (57.1% versus 11.8%, P = 0.018).



Considering the development of NAFLD, adjuvant chemotherapy after PD should be cared for the patients with small remnant pancreas.
Department of Surgery, National Defense Medical College, Saitama, Japan.
Makoto
M
Nishikawa
Department of Surgery, National Defense Medical College, Saitama, Japan.
Suefumi
S
Aosasa
Department of Surgery, National Defense Medical College, Saitama, Japan.
Tomoyuki
T
Moriya
Department of Surgery, National Defense Medical College, Saitama, Japan.
Takuji
T
Noro
Department of Surgery, National Defense Medical College, Saitama, Japan.
Kazuo
K
Hase
Department of Surgery, National Defense Medical College, Saitama, Japan. Electronic address: jyamamot@ndmc.ac.jp.
Junji
J
Yamamoto
D000368:Aged; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000453:epidemiology / Q000209:etiology*; D016577:Pancreaticoduodenectomy; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology*; D012189:Retrospective Studies; D012307:Risk Factors
Adjuvant chemotherapy; Hepatic steatosis; Nonalcoholic fatty liver disease; Pancreatoduodenectomy; Postoperative complication; S-1